Mitochondria as Potential Target in Disease Therapy

A special issue of Future Pharmacology (ISSN 2673-9879).

Deadline for manuscript submissions: closed (10 December 2022) | Viewed by 4012

Special Issue Editors


E-Mail Website
Guest Editor
Department of Cardiovascular Biomedicine, National Institute of Cardiology, Ignacio Chávez, Mexico City 14080, Mexico
Interests: cardiac reperfusion damage; mitochondrial bioenergetics; signal transduction; mitochondrial permeability transition pore

E-Mail Website
Guest Editor
Department of Cardio-Renal Physiopathology, National Institute of Cardiology “Ignacio Chávez”, Mexico City 14080, Mexico
Interests: mitochondrial function; bioenergetics; redox signaling; chronic kidney disease; metabolic reprograming and extracelular vesicles
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The current special issue is designated to publish original articles investigating mitochondria as a therapeutic target in diseases because relevance of the impairment in this organelle in metabolism, immunity, apoptosis, and signal transduction alterations.

Mitochondria are highly dynamic organelles that have a critical role in ROS production, cross talking between redox signaling and metabolic regulation, in cell death regulation and calcium homeostasis. Thus, mitochondria impairment plays a pivotal role in the genesis and development of acute and chronic injuries, triggering pathological pathways like inflammation, oxidative stress and fibrosis. Furthermore, recent use of mitochondrial target therapies has showed promising results in resolve or prevent different pathologies. Therefore, we invite investigators to submit an original research paper or review articles for publication in this Special issue. We are particularly interested in articles related to mitochondrial improvement in diseases such as metabolic diseases, cancer, kidney diseases, hepatic diseases, heart diseases, and more.

Prof. Dr. José Pedraza Chaverri
Prof. Dr. Cecilia Zazueta
Dr. Omar Emiliano Aparicio Trejo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mitochondrial dysfunction
  • mitochondrial therapeutic targets
  • mitochondria and redox signaling
  • metabolic regulation and mitochondria
  • chronic and acute disease and mitochondria
  • mitochondrial regulation in inflammation and fibrosis
  • cell death and calcium regulation by mitochondria

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 1920 KiB  
Review
Promising Therapeutic Strategies Targeting Mitochondria in Kidney Diseases: From Small Molecules to Whole Mitochondria
by Alexis Paulina Jiménez-Uribe and José Pedraza-Chaverri
Future Pharmacol. 2022, 2(3), 256-275; https://doi.org/10.3390/futurepharmacol2030017 - 22 Jul 2022
Cited by 2 | Viewed by 3200
Abstract
Kidney function highly depends on mitochondria, organelles that regulate different metabolic pathways. Mitochondria-altered function and structure are present during acute kidney injury (AKI) and chronic kidney disease (CKD). Targeting mitochondria using several strategies has been shown to improve kidney function. Here, we review [...] Read more.
Kidney function highly depends on mitochondria, organelles that regulate different metabolic pathways. Mitochondria-altered function and structure are present during acute kidney injury (AKI) and chronic kidney disease (CKD). Targeting mitochondria using several strategies has been shown to improve kidney function. Here, we review some experimental mitochondria targeting strategies with clinical potential in kidney diseases encompassing cationic/lipophilic small molecules, peptides, nanocarriers, and even the entire organelle. Full article
(This article belongs to the Special Issue Mitochondria as Potential Target in Disease Therapy)
Show Figures

Figure 1

Back to TopTop